RxDoctor Payments Data

Timothy Atkinson, MD

Urology · Frankfort, KYNPI 1134428808

Payments from drug & device makers

$1,826in general payments, 2019–2025

Across 74 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$350
  • Boston Scientific$209
  • AbbVie$168
  • Medtronic$156
  • Endo Pharmaceuticals Inc.$86
  • Sumitomo Pharma America, Inc.$85
  • plus $772 from 23 others

What the payments were for

  • Food & beverage$1,79999%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,826 in reported general payments places this provider in the 35th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$237,437
Medicare patients
513
Services billed
33,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron241$161,744
MyrbetriqMirabegron200$160,183
Trospium Chloride ErTrospium Chloride75$17,588
Mirabegron ErMirabegron17$13,665
Tamsulosin Hcl762$8,123
XyostedTestosterone Enanthate11$6,576
Finasteride530$6,471
Methenamine Hippurate66$5,521
Potassium Citrate ErPotassium Citrate28$4,915
NitrofurantoinNitrofurantoin Macrocrystal115$3,851
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst234$3,689
Fesoterodine Fumarate ErFesoterodine Fumarate33$2,977
Testosterone Cypionate57$2,841
Testosterone28$2,773
Tolterodine Tartrate ErTolterodine Tartrate20$2,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$85$161,744241 claims
Astellas Pharma US IncMyrbetriq$63$160,183200 claims
Antares Pharma, Inc.Xyosted$48$6,57611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 139 urology providers in Kentucky.

Other urology in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →